Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Coya Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Coya Therapeutics, Inc.’s stock price such as:

• Coya Therapeutics, Inc.’s current stock price and volume
• Why Coya Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for COYA from analysts
• COYA’s stock price momentum as measured by its relative strength

About Coya Therapeutics, Inc. (COYA)

Before we jump into Coya Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Want to learn more about Coya Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Coya Therapeutics, Inc..

Coya Therapeutics, Inc.’s Stock Price as of Market Close

As of September 03, 2026, 12:23 PM, CST, Coya Therapeutics, Inc.’s stock price was $4.430.

Coya Therapeutics, Inc. is up 0.23% from its previous closing price of $4.420.

During the last market session, Coya Therapeutics, Inc.’s stock traded between $4.360 and $4.560. Currently, there are approximately 23.46 million shares outstanding for Coya Therapeutics, Inc..

Coya Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Coya Therapeutics, Inc. Stock Price History

Coya Therapeutics, Inc.’s (COYA) price is currently down 2.85% so far this month.

During the month of September, Coya Therapeutics, Inc.’s stock price has reached a high of $4.650 and a low of $4.360.

Over the last year, Coya Therapeutics, Inc. has hit prices as high as $7.750 and as low as $3.710. Year to date, Coya Therapeutics, Inc.’s stock is down 23.62%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Coya Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 02, 2026, there were 0 analysts who downgraded Coya Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Coya Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Coya Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Coya Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Coya Therapeutics, Inc. (COYA) by visiting AAII Stock Evaluator.

Relative Price Strength of Coya Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 02, 2026, Coya Therapeutics, Inc. has a weighted four-quarter relative price strength of -12.80%, which translates to a Momentum Score of 18 and is considered to be Very Weak.

Want to learn more about how Coya Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Coya Therapeutics, Inc. Stock Price: Bottom Line

As of September 3, 2026, Coya Therapeutics, Inc.’s stock price is $4.430, which is up 0.23% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Coya Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.